Scarica l'app Stockscreener
0.55
7.87%
-0.047
Dopo l'orario di chiusura:
.57
0.02
+3.64%
Windtree Therapeutics Inc Borsa (WINT) Ultime notizie
Warrington’s Windtree Therapeutics Acquires Waste Management Company - MSN
Windtree Therapeutics Announces Promising Phase 2 Study Results for Istaroxime - MyChesCo
Windtree Therapeutics (WINT) Publishes Promising Phase 2 Study R - GuruFocus
Ratios Revealed: Decoding Windtree Therapeutics Inc (WINT)’s Financial Health - DWinneX
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study | WINT Stock News - GuruFocus
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study - Yahoo Finance
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Up 70.4% in May - Defense World
Windtree Therapeutics Acquires Titan Environmental Services to Drive Profitability - MSN
Windtree Therapeutics Receives $7 Million Offer for Preclinical Oncology Platform - MSN
Titan Environmental to be acquired by Windtree Therapeutics - Investing.com Nigeria
Titan Environmental to be acquired by Windtree Therapeutics By Investing.com - Investing.com South Africa
Windtree Therapeutics Stock Is Volatile This Week: What's Going On? - Benzinga
Windtree Therapeutics to acquire Titan Environmental Services - MSN
Windtree Therapeutics receives $7M offer for oncology platform By Investing.com - Investing.com South Africa
Warrington’s Windtree Therapeutics Acquires A Waste Management Company - BUCKSCO.Today
Windtree Therapeutics Raises $3.9M Through Note Agreements - TipRanks
Windtree Therapeutics (WINT) Receives Offer for Oncology Platfor - GuruFocus
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate - The Manila Times
Windtree Therapeutics (WINT) Receives Offer for Oncology Platform | WINT Stock News - GuruFocus
Windtree Therapeutics receives offer for preclinical oncology drug candidate - TipRanks
Windtree Therapeutics receives $7M offer for oncology platform - Investing.com Australia
Windtree Therapeutics, Inc. Secures $7 Million Up Front for Preclinical Oncology Drug Candidate, Potentially Worth $130 Million in Milestones and $1.5 Billion in Royalties - Nasdaq
Windtree's $1.5 Billion Oncology Drug Deal Signals Major Strategic ShiftSee Full Terms - Stock Titan
Working to clean up its finances, Windtree Therapeutics gets into the garbage business - The Business Journals
Windtree to Acquire Titan Environmental Services; Shares Surge - MarketScreener
Windtree Stock Is Rising Tuesday: What's Going On? - Benzinga
Windtree Therapeutics (WINT) to Acquire Titan Environmental Serv - GuruFocus
Windtree Announces Transformational Agreement To Acquire Revenue Generating Environmental Services Business - marketscreener.com
Windtree Therapeutics announces agreement to acquire Titan Environmental - TipRanks
Windtree Therapeutics (WINT) Acquires Titan Environmental Services to Enhance Profitability | WINT Stock News - GuruFocus
Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business - Yahoo Finance
Windtree Therapeutics Announces Move into Cryptocurrency Payments and Holdings - MSN
Windtree Announces Plan for Cryptocurrency Treasury Policy | WIN - GuruFocus
Windtree Therapeutics to accept cryptocurrency payments - Investing.com Australia
Windtree Therapeutics to accept cryptocurrency payments By Investing.com - Investing.com South Africa
Windtree Therapeutics announces plan for cryptocurrency treasury policy - TipRanks
Windtree Therapeutics (WINT) Embraces Cryptocurrency as Payment Option | WINT Stock News - GuruFocus
Windtree Therapeutics (WINT) to Accept Cryptocurrency Payments: A Strategic Shift Amid Financial Challenges - Coinfomania
Windtree Therapeutics Creates Cryptocurrency Treasury Plan - MarketScreener
Windtree Therapeutics IncTo Create Cryptocurrency Policy For Payments And Assets - marketscreener.com
Major Biotech Company Windtree Embraces Crypto: Plans Bitcoin Payments and Digital Asset Treasury Strategy - Stock Titan
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Increases By 110.2% - Defense World
Windtree Therapeutics Targets July for Interim Data from Key Cardiogenic Shock Study - MSN
Windtree Showcases Promising Istaroxime Data for Cardiogenic Shock at Major Conference - MSN
Windtree Therapeutics (WINT) Targets Key Study Analysis for July 2025 | WINT Stock News - GuruFocus
Windtree says interim results for SEISMiC SCAI Stage C study set for July 2025 - TipRanks
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - marketscreener.com
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 | WINT Stock News - GuruFocus
Windtree Therapeutics Advances Istaroxime Cardiogenic Shock Program with SEISMiC C Study Interim Analysis Planned for July 2025 - Nasdaq
Critical Phase 2 Data Coming for Istaroxime in Severe Cardiogenic Shock Treatment - Stock Titan
2.13%
1.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):